Here are the 10-K annual reports from Salarius Pharmaceuticals, Inc. (SLRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SLRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLRX filings page.
Decoy Therapeutics Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add Part III information on directors, executive officers, compensation, ownership and auditor fees because it will not file a proxy within 120 days of year‑end.
The filing details a seven‑member classified board with independent committee structures, recent leadership changes following the merger with Legacy Decoy, and 2025 pay for named executives, including a transaction bonus for the CFO and a 2024 severance package for the former CEO. It also describes equity incentive plans, director retainers, related‑party notes, and audit fees paid to Ernst & Young LLP.
Decoy Therapeutics Inc. files its annual report describing a preclinical-stage biotechnology business built around the AI- and machine-learning–enabled IMP3ACT™ peptide conjugate platform. The company is developing Designable Multi-Antivirals targeting conserved viral fusion mechanisms, led by a nasally inhaled pan-coronavirus prophylactic for immunocompromised patients and a planned broad respiratory antiviral for flu, COVID-19, and RSV.
The report details the November 2025 merger with Legacy Decoy, a subsequent name and ticker change, and two reverse stock splits (1-for-15 in 2025 and 1-for-12 in 2026) used alongside capital raises to maintain Nasdaq listing compliance. Management highlights substantial doubt about the company’s ability to continue as a going concern, ongoing operating losses, reliance on future financings and non‑dilutive grants, and early-stage programs that have not yet generated product revenue.